Patients with resistant hypertension are at risk for poor outcomes. Medication adherence
and intensification improve blood pressure (BP) control; however, little is known about these …

Intensive monitoring of adherence in patients with uncontrolled hypertension was evaluated
over a 6‐month period. After that period, only patients well characterized as having resistant …

Non-adherence has been a major concern in the treatment of hypertension and is
particularly important in understanding and intervening in patients who appear to have …

Most studies on the prevalence and determinants of resistant hypertension (RH) do not
account for white coat hypertension, medication non-adherence, or use of suboptimal …

Resistant hypertension is common among the hypertensive population with reported
prevalence of 12 to 15%. These patients have a higher cardiovascular risk and …

Resistant hypertension (RHTN) can be defined as the failure to achieve the goal blood
pressure (less than 140/90 mm Hg, for the overall population, and less than 130/80 mm Hg …

Objectives: Medication nonadherence is a known behavioural contributor to poor blood
pressure (BP) control that puts patients with hypertension at elevated cardiovascular risk …

The actual development of new drugs for hypertension is slow. Thus, focusing on drug
adherence to the drugs available is an important way to improve blood pressure control in …

Aims Hypertension is only controlled in approximately 35% of the patients, which could be
partially due to nonadherence. Recently, bioanalytical assessment of adherence to blood …

Background: Nonadherence to drug therapy poses a significant problem in the treatment of
patients with presumed resistant hypertension. It has been shown that therapeutic drug …